Roche Pays $40M to Use Amunix’s Half-Life Extension Tech

Roche will pay Amunix Pharmaceuticals $40 million upfront to use the company’s proprietary technology to discover and develop new drugs outside of the oncology space. The clinically validated platform—XTEN—is a proprietary unstructured polypeptide, which when attached to molecules, can extend the half-life of drugs with low associated immunogenicity, according to Amunix. As per the agreement, […]

Click to view original post